Cross-Cohort Omics Integration and External Validation Service

Separate Center Effects From Reproducible Biology

Your question: Does the main signal remain when one center, sequencing site, processing batch, or collection period is left out?

Data required: Molecular profiles plus sample-level center, run, protocol, processing, biological-group, and composition metadata. Replicate or reference samples are especially useful when they were measured at more than one site.

Analysis route: We compare center and group balance, data-quality measures, feature distributions, sample composition, and within-center effect directions. Depending on the design, we may use center-stratified models, shared-reference normalization, leave-one-center-out analysis, or pooled analysis with center-aware sensitivity checks.

Scientist check: We test whether center is separable from the biological contrast and whether the proposed adjustment preserves within-center relationships. If a group occurs only at one center, the data may not identify a center-independent effect.

What we deliver: A center and batch assessment, cohort-level results, sensitivity analysis, and a statement of which conclusions remain supported.

Method evidence: Nygaard, Rødland, and Hovig showed that when biological groups are unevenly distributed across batches, adjustment methods that retain group differences can create exaggerated confidence in downstream analyses. Their work supports reviewing design balance and inference, not only the corrected matrix. Read the Biostatistics study.

Applied evidence: The GEUVADIS consortium sequenced mRNA and small RNA from 465 individuals across seven sequencing centers with extensive replication. The study identified laboratory effects in measures such as insert size and GC content and emphasized standardization, randomization, and explicit technical-bias checks. Read the Nature Biotechnology study.

Test a Finding in Public or Partner Cohorts

Your question: Does a biomarker, subtype, pathway score, target signal, or molecular signature reproduce in data that did not create it?

Data required: The locked discovery rule and one or more scientifically suitable public, licensed, partner-center, or internal cohorts with enough metadata and feature overlap to perform the intended test.

Analysis route: We document the finding before validation, audit participant and source-study overlap, align eligibility and feature definitions, and keep the external cohort outside feature selection and rule revision. We then compare effect direction, magnitude, uncertainty, and subgroup support.

Scientist check: A revised rule created after viewing the external result is labeled as a new discovery and is not counted as independent confirmation. It requires another untouched cohort for a new external test.

What we deliver: Cohort-specific replication, partial replication, or non-replication results; conflicting evidence; failure analysis; and a focused next-study recommendation.

Method evidence: Bernau et al. evaluated prediction methods across eight independent breast-cancer gene-expression studies. Within-study cross-validation produced more optimistic estimates than cross-study validation and could rank methods differently, showing why a new study provides information that resampling one dataset cannot. Read the Bioinformatics study.

Applied evidence: Ning et al. analyzed nine metagenomic and four metabolomics cohorts. Their metagenomic design contained six discovery cohorts and three independent validation cohorts, and the reported validation results differed among the external cohorts. Read the Nature Communications study.

Determine Whether a Result Transfers Across Platforms

Your question: Can a finding developed on one assay or platform be tested on another without changing what the measurement means?

Data required: Raw or processed data, assay documentation, feature identifiers, reference versions, units, processing records, platform coverage, and any shared reference or bridge samples.

Analysis route: We map identifiers and units, quantify common coverage, inspect platform-specific detection behavior, and choose a comparison scale supported by the data. Depending on the evidence, that scale may be relative change, rank, direction, pathway score, or study-level effect rather than absolute abundance.

Scientist check: We do not force one-to-one mapping when platforms measure different targets or resolutions. When computational mapping cannot establish comparability, we define common-platform remeasurement or a bridge-sample experiment.

What we deliver: A platform mapping record, comparable feature set, cross-platform consistency results, unresolved measurement gaps, and a bridge recommendation when needed.

Method evidence: Ramasamy et al. organized cross-study expression meta-analysis into study identification, dataset preparation, annotation, probe-to-gene mapping, study-specific estimation, evidence combination, and heterogeneity interpretation. This supports evidence-level combination when raw values are not exchangeable. Read the PLOS Medicine framework.

Applied benchmark: The SEQC/MAQC-III consortium assessed common reference RNA across laboratories and sequencing platforms and compared RNA-seq with microarray and qPCR measurements. Relative expression could be reproducible with suitable filters, while absolute measurement and transcript-level results had important platform-dependent limits. Read the Nature Biotechnology benchmark.

Define Where a Finding Stops Transferring

Your question: Is the result supported across populations, extraction protocols, tissue sources, disease stages, models, treatments, or study conditions?

Data required: Independent cohorts representing the intended research settings, protocol records, and metadata that describe the differences likely to affect transfer.

Analysis route: We compare cohort-level effects, uncertainty, heterogeneity, subgroup behavior, feature detection, processing protocols, and reasonable analysis choices. Held-out-study or leave-one-cohort-out tests are used when the number and structure of cohorts support them.

Scientist check: We separate observed protocol effects from biological heterogeneity only when the metadata and design permit that conclusion. A result supported in one population or protocol is not described as universally transferable.

What we deliver: An evidence matrix marking supported, uncertain, and unsupported settings, together with the observed transferability boundary and the evidence needed to extend it.

Method evidence: Austin et al. examined organism-specific processing bias and held-out-study generalization across microbiome datasets. Their DEBIAS-M work shows why extraction, amplification, and other protocol differences should be modeled as interpretable sources of domain shift rather than treated as one generic batch label. Read the Nature Microbiology study.

Applied evidence: Xiao, Zhang, and Zhao analyzed 2,742 microbiome datasets from seven independent studies in China, Germany, and the United States. In their example, between-study differences were greater than the target group difference, and some taxa changed direction among studies. Read the Nature Computational Science study.